TABLE 1.
Identified protein targets for lisdexamfetamine (Gutiérrez-Casares et al., 2021).
| Gene name | Protein name | Effect* | Reference of LDX target |
| TAAR1 | Trace amine-associated receptor 1 | 1 | Ekstrand et al., 2019 |
| SLC18A2 | Synaptic vesicular amine transporter (VMAT2) | −1 | Hutson et al., 2014; Ekstrand et al., 2019 |
| SLC6A3 | Sodium-dependent dopamine transporter (DAT) | −1 | Cheney et al., 2014; Hutson et al., 2014; Strajhar et al., 2019 |
| SLC6A2 | Sodium-dependent noradrenaline transporter (NET) | −1 | Cheney et al., 2014; Hutson et al., 2014 |
| SLC6A4 | Sodium-dependent serotonin transporter (SERT) | −1 | Hutson et al., 2014 |
| MAOA | Amine oxidase (flavin-containing) A | −1 | Dew and Kollins, 2010; Cheney et al., 2014 |
| MAOB | Amine oxidase (flavin-containing) B | −1 | Dew and Kollins, 2010; Cheney et al., 2014 |
*Effect refers to the drug’s action on the protein, 1 denotes activation of protein function, −1 inhibition of protein function. LDX, lisdexamfetamine.